Christopher Pierce - Net Worth and Insider Trading
Christopher Pierce Net Worth
The estimated net worth of Christopher Pierce is at least $9,713 dollars as of 2024-09-20. Christopher Pierce is the EVP and Chief of Business Oper of Prelude Therapeutics Inc and owns about 3,750 shares of Prelude Therapeutics Inc (PRLD) stock worth over $9,713. Details can be seen in Christopher Pierce's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Christopher Pierce has not made any transactions after 2021-09-02 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Christopher Pierce
Christopher Pierce Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Christopher Pierce owns 1 companies in total, including Prelude Therapeutics Inc (PRLD) .
Click here to see the complete history of Christopher Pierce’s form 4 insider trades.
Insider Ownership Summary of Christopher Pierce
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| PRLD | Prelude Therapeutics Inc | 2021-09-02 | EVP and Chief of Business Oper |
Christopher Pierce Latest Holdings Summary
Christopher Pierce currently owns a total of 1 stock. Christopher Pierce owns 3,750 shares of Prelude Therapeutics Inc (PRLD) as of September 2, 2021, with a value of $9,713.
Latest Holdings of Christopher Pierce
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| PRLD | Prelude Therapeutics Inc | 2021-09-02 | 3,750 | 2.59 | 9,713 |
Holding Weightings of Christopher Pierce
Christopher Pierce Form 4 Trading Tracker
According to the SEC Form 4 filings, Christopher Pierce has made a total of 5 transactions in Prelude Therapeutics Inc (PRLD) over the past 5 years, including 1 buys and 4 sells. The most-recent trade in Prelude Therapeutics Inc is the sale of 17,000 shares on September 2, 2021, which brought Christopher Pierce around $708,560.
Insider Trading History of Christopher Pierce
- 1
Christopher Pierce Trading Performance
GuruFocus tracks the stock performance after each of Christopher Pierce's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Christopher Pierce is 191.75%. GuruFocus also compares Christopher Pierce's trading performance to market benchmark return within the same time period. The performance of stocks bought by Christopher Pierce within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Christopher Pierce's insider trading performs compared to the benchmark.
Performance of Christopher Pierce
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 20.6 | | | | | |
| Relative Return to S&P 500(%) | 21.36 | | | | | |
Christopher Pierce Ownership Network
Christopher Pierce Owned Company Details
What does Prelude Therapeutics Inc do?
Who are the key executives at Prelude Therapeutics Inc?
Christopher Pierce is the EVP and Chief of Business Oper of Prelude Therapeutics Inc. Other key executives at Prelude Therapeutics Inc include director & President & CEO Krishna Vaddi , Chief Legal Counsel & Corp Sec. Bryant David Lim , and Chief Financial Officer Laurent Chardonnet .
Prelude Therapeutics Inc (PRLD) Insider Trades Summary
Over the past 18 months, Christopher Pierce made no insider transaction in Prelude Therapeutics Inc (PRLD). Other recent insider transactions involving Prelude Therapeutics Inc (PRLD) include a net purchase of 13,756 shares made by Krishna Vaddi , a net purchase of 869,565 shares made by Orbimed Advisors Llc , and a net purchase of 869,565 shares made by David P Bonita .
In summary, during the past 3 months, insiders sold 0 shares of Prelude Therapeutics Inc (PRLD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 13,280 shares of Prelude Therapeutics Inc (PRLD) were sold and 1,760,286 shares were bought by its insiders, resulting in a net purchase of 1,747,006 shares.
Prelude Therapeutics Inc (PRLD)'s detailed insider trading history can be found in Insider Trading Tracker table.
Prelude Therapeutics Inc Insider Transactions
Christopher Pierce Mailing Address
Above is the net worth, insider trading, and ownership report for Christopher Pierce. You might contact Christopher Pierce via mailing address: C/o Prelude Therapeutics Incorporated, 200 Powder Mill Road, Wilmington De 19803.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
